Treatment of refractory autoimmune diseases with autologous stem cell transplantation: Focus on juvenile idiopathic arthritis

Bone Marrow Transplantation

Volumn 35, Issue , 2005, Pages S27-S29

  Wulffraat, N M ^a   Vastert, B ^a   Tyndall, A ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Autologous stem cell transplantation (ASCT); Juvenile idiopathic arthritis (JIA); Refractory

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FLUDARABINE; GOLD; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 6 ANTIBODY; METHOTREXATE; METHYLPREDNISOLONE; SALAZOSULFAPYRIDINE; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ARTICLE; AUTOIMMUNE DISEASE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CHILD; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG MEGADOSE; ERYTHROPHAGOCYTOSIS; FEASIBILITY STUDY; FOLLOW UP; HIGH RISK PATIENT; HUMAN; INBORN ERROR OF METABOLISM; INFANT; INFECTION; JUVENILE RHEUMATOID ARTHRITIS; MORTALITY; NATURAL KILLER CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; SAFETY; SIDE EFFECT; TREATMENT FAILURE;

ARTHRITIS, JUVENILE RHEUMATOID; FEMALE; HUMANS; MALE; REMISSION INDUCTION; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS;

EID: 18144367378     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704840     Document Type: Article

References (21)

1. van Bekkum DW. Stem cell transplantation for autoimmune disorders. Preclinical experiments. Best Pract Res Clin Haematol 2004; 17: 201-222.
2. Marmont AM. Stem cell transplantation for autoimmune disorders. Coincidental autoimmune disease in patients transplanted for conventional indications. Best Pract Res Clin Haematol 2004; 17: 223-232.
3. Wallace CA, Sherry DD. Trial of intravenous pulse cyclophosphamide and methylprednisolone in the treatment of severe systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum 1997; 40: 1852-1855.
4. Lovell DJ, Giannini EH, Reiff A et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000; 342: 763-769.
5. Yokota S. Interleukin 6 as a therapeutic target in systemiconset juvenile idiopathic arthritis. Curr Opin Rheumatol 2003; 15: 581-586.
6. Quartier P, Taupin P, Bourdeaut F et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003; 48: 1093-1101.
7. Petty RE. Prognosis in children with rheumatic diseases: justification for consideration of new therapies. Rheumatology (Oxford) 1999; 38: 739-742.
8. Spiegel LR, Schneider R, Lang BA et al. Early predictors of poor functional outcome in systemic-onset juvenile rheumatoid arthritis: a multicenter cohort study. Arthritis Rheum 2000; 43: 2402-2409.
9. Giannini EH, Ruperto N, Ravelli A et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997; 40: 1202-1209.
10. Ruperto N, RavelliA, Falcini F et al. Performance of the preliminary definition of improvement in juvenile chronic arthritis patients treated with methotrexate. Italian Pediatric Rheumatology Study Group. Ann Rheum Dis 1998; 57: 38-41.
11. De Kleer IM, Brinkman DM, Ferster A et al. Autologous stem cell transplantation for refractory juvenile idiopathic arthritis: analysis of clinical efficacy mortality and transplant related morbidity. Ann Rheum Dis 2004; 63: 1318-1326.
12. Wulffraat NM, Brinkman D, Ferster A et al. Long-term follow-up of autologous stem cell transplantation for refractory juvenile idiopathic arthritis. Bone Marrow Transplant 2003; 32 (Suppl. 1): S61-S64.
13. Ramanan AV, Schneider R. Macrophage activation syndrome - what's in a name!. J Rheumatol 2003; 30: 2513-2516.
14. Ravelli A, De Benedetti F, Viola S, Martini A. Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. J Pediatr 1996; 128: 275-278.
15. Stephan JL, Kone-Paut I, Galambrun C et al. Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients. Rheumatology (Oxford) 2001; 40: 1285-1292.
16. Silverman ED, Miller III JJ, Bernstein B, Shafai T. Consumption coagulopathy associated with systemic juvenile rheumatoid arthritis. J Pediatr 1983; 103: 872-876.
17. Hertzberger-ten Cate R, Cats A. Toxicity of sulfasalazine in systemic juvenile chronic arthritis. Clin Exp Rheumatol 1991; 9: 85-88.
18. Prahalad S, Bove KE, Dickens D et al. Etanercept in the treatment of macrophage activation syndrome. J Rheumatol 2001; 28: 2120-2124.
19. Ravelli A, Caria MC, Buratti S et al. Methotrexate as a possible trigger of macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol 2001; 28: 865-867.
20. Grom AA, Villanueva J, Lee S et al. Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. J Pediatr 2003; 142: 292-296.
21. Wulffraat NM, Rijkers GT, Elst EF et al. Reduced perforin expression in systemic juvenile idiopathic arthritis is restored by autologous stem cell transplantation. Rheumatology (Oxford) 2003; 42: 375-379.